U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386210) titled 'Antihypertensive Effects of Rosmarinus Officinalis L. Infusion' on Jan. 11.
Brief Summary: This study assessed the antihypertensive effect of rosemary tea through a placebo-controlled clinical study, angiotensin-converting enzyme (ACE) inhibition analysis, and in silico evaluation of interactions between rosemary bioactive compounds and the AT1R (Angiotensin II Type 1 Receptor).
A randomized, double-blind, placebo-controlled trial was conducted in 54 male patients with mild hypertension. Participants were assigned to receive either rosemary infusion (n = 27) or placebo (n = 23) for 45 days. Ambulatory blood pressure monitoring wass ...